Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Smit

Showing results (361-370 of 692) with videos related to

Pageof 70
Sort By:
Respiratory Research|October 3, 2008
Membrane diffusion- and capillary blood volume measurements are not useful as screening tools for pulmonary arterial hypertension in systemic sclerosis: a case control studyMaria J Overbeek, Herman Groepenhoff, Alexandre E Voskuyl, et al.
European Journal of Clinical Nutrition|January 12, 2012
Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCTB S van der Meij, J A E Langius, M D Spreeuwenberg, et al.
Lung Cancer (Amsterdam, Netherlands)|August 15, 2012
Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatinMarcello Tiseo, Elisa Giovannetti, Carmelo Tibaldi, et al.
Lung Cancer (Amsterdam, Netherlands)|October 10, 2012
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatinMartin Reck, Nick Thatcher, Egbert F Smit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1991
Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic studyE F Smit, P H Willemse, D T Sleijfer, et al.
EJNMMI Research|August 18, 2020
Quantification of [<sup>18</sup>F]afatinib using PET/CT in NSCLC patients: a feasibility studyE A van de Stadt, M Yaqub, A A Lammertsma, et al.
The Lancet. Oncology|September 19, 2017
Dabrafenib plus trametinib in patients with previously untreated BRAF<sup>V600E</sup>-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trialDavid Planchard, Egbert F Smit, Harry J M Groen, et al.
Plos One|July 31, 2024
Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancerKarlijn Hummelink, Vincent van der Noort, Mirte Muller, et al.
Journal of Cancer Research and Clinical Oncology|June 26, 2024
Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?Melda Yeghaian, Teresa M Tareco Bucho, Melissa de Bruin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 7, 2011
Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysisPatsuree Cheebsumon, Linda M Velasquez, Corneline J Hoekstra, et al.
Pageof 70

Showing results (361-370 of 692) with videos related to

Sort By:
Pageof 70
Respiratory Research|October 3, 2008
Membrane diffusion- and capillary blood volume measurements are not useful as screening tools for pulmonary arterial hypertension in systemic sclerosis: a case control studyMaria J Overbeek, Herman Groepenhoff, Alexandre E Voskuyl, et al.
European Journal of Clinical Nutrition|January 12, 2012
Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCTB S van der Meij, J A E Langius, M D Spreeuwenberg, et al.
Lung Cancer (Amsterdam, Netherlands)|August 15, 2012
Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatinMarcello Tiseo, Elisa Giovannetti, Carmelo Tibaldi, et al.
Lung Cancer (Amsterdam, Netherlands)|October 10, 2012
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatinMartin Reck, Nick Thatcher, Egbert F Smit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1991
Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic studyE F Smit, P H Willemse, D T Sleijfer, et al.
EJNMMI Research|August 18, 2020
Quantification of [<sup>18</sup>F]afatinib using PET/CT in NSCLC patients: a feasibility studyE A van de Stadt, M Yaqub, A A Lammertsma, et al.
The Lancet. Oncology|September 19, 2017
Dabrafenib plus trametinib in patients with previously untreated BRAF<sup>V600E</sup>-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trialDavid Planchard, Egbert F Smit, Harry J M Groen, et al.
Plos One|July 31, 2024
Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancerKarlijn Hummelink, Vincent van der Noort, Mirte Muller, et al.
Journal of Cancer Research and Clinical Oncology|June 26, 2024
Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?Melda Yeghaian, Teresa M Tareco Bucho, Melissa de Bruin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 7, 2011
Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysisPatsuree Cheebsumon, Linda M Velasquez, Corneline J Hoekstra, et al.
Pageof 70